Grifols is a Spanish multinational pharmaceutical and chemical company that specializes in the production of plasma-derived medicines, diagnostic systems, and hospital pharmacy products. The company is headquartered in Barcelona, Spain. Grifols was founded in 1940 by Dr.

José Antonio Grifols Roig. Initially, it focused on the production of blood plasma-derived products. Over the years, the company expanded its product portfolio and established itself as a global leader in the industry.

In 1987, Grifols became the first European company to collect and fractionate plasma for the production of medicines. The company’s headquarters, known as the Grifols Campus, is located in Barcelona, Spain. The campus is home to various research and production facilities, including laboratories, cleanrooms, and manufacturing plants.

It serves as the central hub for the company's operations and allows for close collaboration between different departments. Grifols offers a wide range of products and services, including plasma-derived medicines such as immunoglobulins, albumin, factor VIII, and other therapies for rare diseases. The company also provides diagnostic systems and reagents for blood typing and disease screening, as well as hospital pharmacy products like bags for parenteral nutrition and infusion systems.

Grifols operates globally and has a presence in more than 100 countries. The company has numerous subsidiaries and joint ventures, including Biomat USA, a leading plasma collection network in the United States, and Talecris Biotherapeutics, a company specializing in the production of plasma proteins. Grifols also has partnerships with other pharmaceutical companies, research institutions, and healthcare organizations to further enhance its capabilities and expand its product offerings.

In terms of market position, Grifols is one of the major players in the global plasma-derived therapies market. It has a significant market share and competes with other major pharmaceutical companies such as CSL Behring, Baxter International, and Octapharma. Grifols' global sales have been steadily growing, driven by its diverse product portfolio and strong presence in key markets.

In recent years, Grifols has made significant advancements in plasma collection and fractionation technologies, allowing for increased production and improved product quality. The company has also expanded its research and development efforts, focusing on the development of innovative therapies for rare diseases. Overall, Grifols continues to thrive as a global leader in the pharmaceutical industry.

Its commitment to research, development, and quality ensures its position as a trusted provider of life-saving therapies